InvestorsHub Logo
Followers 73
Posts 3615
Boards Moderated 0
Alias Born 03/23/2013

Re: None

Saturday, 08/06/2022 7:20:45 PM

Saturday, August 06, 2022 7:20:45 PM

Post# of 427337
I believe AMRN "could" still be a $30.00 volcano stock.

Clearly things are not going well for the company and their GIA endeavors... but there is still hope.
As you know, I will not buy and hold a stock unless FA + TA are in bullish sync.

Here is how that could happen:

Covid-19 infection and Covid-19 vaccinations exert adverse side effects on the cardio-vascular system - including Alzheimer’s like symptoms (Alzheimer's-like changes found in COVID patients' brains).

The more I think about this, the more I realize how important the MITIGATE results will be. If they show efficacy towards mitigating these nasty symptoms and lingering side effects then they will also show amplified line separation that validates R-It results (W/o the use of mineral oil).
That would be fantastic... but the real kicker will be a similar amplified effect in the BRAVE trial due to V's MOA in terms of endothelial repair and mitigation of amyloid plaque formation in opposition to the placebo group who potentially could deteriorate quicker as a result of COVID-19.

From the Reuter's article above:

People who die of severe COVID-19 have brain abnormalities that resemble changes seen in Alzheimer's disease - accumulation of a protein called tau inside brain cells, and abnormal amounts of the protein beta-amyloid that accumulates into amyloid plaques - small studies have found.



So MITIGATE is huge. Amarin management keeps blaming Covid for their lack of sales and stagnation, but perhaps (ironically) they should be thanking their lucky stars because of the COVID impact on these trials which could really tip the scale towards significance beyond expectation in favor of Vascepa.

The other thought I had is if this theory is true, the TA divergence with these potential findings presents a JL type asymmetric investment with more explosive potential than what we experienced with the R-IT announcement eruption -- as the result of a most certain quick bidding war for the drug.

Could this be the reason why there is so much effort to discredit the R-IT results and kill the stock price?

Is this theory the very reason why Denner bought in so heavily? Is it why he has continued to hold on despite his -80% loss?

My plan is to wait and grab a technical reversal that shows spirited volume. It will come, but at potentially lower levels. Obviously all bets are off if bankruptcy comes into play... they have to maintain their cash until this news breaks.

IMO, we are headed towards the companies most important pivot point. Someone will know these results beforehand and we'll see it on charts or in option buying. We'll likely see a spike out of nowhere at the end of a session from short covering or FOMO buying, leading to a quick runup.

And the music 'keeps playing' (rumbling??)...
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News